麻醉交接与成人心脏手术后1年死亡率的相关性
这项在加拿大安大略省开展的回顾性队列研究纳入2008至2019年接受冠状动脉旁路移植或主动脉、二尖瓣、三尖瓣、胸主动脉手术的102156例成人患者。完全麻醉交接(由替换的麻醉医师完成手术)发生于1926例(1.9%),与30天死亡率(HR 1.89;95%CI 1.41-2.54)和1年死亡率(HR 1.66;95%CI 1.31-2.12)升高相关,同时ICU住院时间(RR 1.43;95%CI 1.22-1.68)和总住院时间(RR 1.17;95%CI 1.06-1.28)延长。交接与患者定义的不良心脏和非心脏事件(PACE)无统计学显著关联(30天:HR 1.09;95%CI 0.79-1.49;1年:HR 0.89;95%CI 0.70-1.13)。作者认为需要进一步研究以定性评估和系统改善交接过程。
要点
- 心脏手术中完全麻醉交接发生率为1.9%(1926/102156),与30天死亡率升高相关(HR 1.89;95%CI 1.41-2.54)。
- 麻醉交接与1年死亡率升高相关(HR 1.66;95%CI 1.31-2.12)。
- 麻醉交接与ICU住院时间延长相关(RR 1.43;95%CI 1.22-1.68),与总住院时间延长相关(RR 1.17;95%CI 1.06-1.28)。
- 麻醉交接与PACE无统计学显著关联(30天:HR 1.09;95%CI 0.79-1.49;1年:HR 0.89;95%CI 0.70-1.13)。
- 作者认为需要进一步研究以定性评估和系统改善交接过程。
适用人群与场景
- 加拿大安大略省居民,年龄≥18岁,2008至2019年接受冠状动脉旁路移植或主动脉、二尖瓣、三尖瓣、胸主动脉手术。
- 排除标准:非安大略省居民身份和其他同期手术。
研究设计与关键结果
- 回顾性队列研究,纳入102156例患者,其中女性25207例(24.7%),平均(SD)年龄66.4(10.8)岁,72843例手术(71.3%)在教学医院进行。
- 麻醉交接发生于1926例(1.9%),与30天死亡率升高相关(HR 1.89;95%CI 1.41-2.54),与1年死亡率升高相关(HR 1.66;95%CI 1.31-2.12)。
- 麻醉交接与ICU住院时间延长相关(RR 1.43;95%CI 1.22-1.68),与总住院时间延长相关(RR 1.17;95%CI 1.06-1.28)。
- 麻醉交接与PACE无统计学显著关联(30天:HR 1.09;95%CI 0.79-1.49;1年:HR 0.89;95%CI 0.70-1.13)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为需要进一步研究以定性评估和系统改善交接过程。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Handovers of anesthesia care from one anesthesiologist to another is an important intraoperative event. Despite its association with adverse events after noncardiac surgery, its impact in the context of cardiac surgery remains unclear.
OBJECTIVE: To compare the outcomes of patients who were exposed to anesthesia handover vs those who were unexposed to anesthesia handover during cardiac surgery.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study in Ontario, Canada, included Ontario residents who were 18 years or older and had undergone coronary artery bypass grafting or aortic, mitral, tricuspid valve, or thoracic aorta surgical procedures between 2008 and 2019. Exclusion criteria were non-Ontario residency status and other concomitant procedures. Statistical analysis was conducted from April 2021 to June 2021, and data collection occurred between November 2020 to January 2021.
EXPOSURES: Complete handover of anesthesia care, where the case is completed by the replacement anesthesiologist.
MAIN OUTCOMES AND MEASURES: The coprimary outcomes were mortality within 30 days and 1 year after surgery. Secondary outcomes were patient-defined adverse cardiac and noncardiac events (PACE), intensive care unit (ICU), and hospital lengths of stay (LOS). Inverse probability of treatment weighting based on the propensity score was used to estimate adjusted effect measures. Mortality was assessed using a Cox proportional hazard model, PACE using a cause-specific hazard model with death as a competing risk, and LOS using Poisson regression.
RESULTS: Of the 102 156 patients in the cohort, 25 207 (24.7%) were women; the mean (SD) age was 66.4 (10.8) years; and 72 843 of surgical procedures (71.3%) were performed in teaching hospitals. Handover occurred in 1926 patients (1.9%) and was associated with higher risks of 30-day mortality (hazard ratio [HR], 1.89; 95% CI, 1.41-2.54) and 1-year mortality (HR, 1.66; 95% CI, 1.31-2.12), as well as longer ICU (risk ratio [RR], 1.43; 95% CI, 1.22-1.68) and hospital (RR, 1.17; 95% CI, 1.06-1.28) LOS. There was no statistically significant association between handover and PACE (30 days: HR 1.09; 95% CI, 0.79-1.49; 1 year: HR 0.89; 95% CI, 0.70-1.13).
CONCLUSIONS AND RELEVANCE: Handover of anesthesia care during cardiac surgical procedures was associated with higher 30-day and 1-year mortality rates and increased health care resource use. Further research is needed to evaluate and systematically improve the handover process qualitatively.
参考来源
- Sun LY, Jones PM, Wijeysundera DN, et al. Association Between Handover of Anesthesiology Care and 1-Year Mortality Among Adults Undergoing Cardiac Surgery. JAMA Netw Open. 2022. PMID: 35147683. doi:10.1001/jamanetworkopen.2021.48161
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。